EULAR 2023 recommendations for SLE treatment: synopsis for the management of lupus nephritis: the European Renal Association–Immunonephrology Working Group (ERA-IWG) perspective.

The article provides an overview of the 2023 recommendations for the treatment of lupus nephritis (LN) from the European Alliance of Associations for Rheumatology (EULAR). The recommendations emphasize the use of belimumab and voclosporin as add-on therapies for managing active LN. Clinical trials have shown that these medications can improve remission rates and reduce kidney damage. The update also discusses the duration of immunosuppression therapy and the potential value of sodium-glucose cotransporter 2 inhibitors as nephroprotective treatment. The future of LN treatment looks promising with the development of newer therapies and the importance of biomarkers in detecting disease activity and response to therapy. [Extracted from the article]

Copyright of Nephrology Dialysis Transplantation is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)